Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III StudyHans von der Maase, PierFranco Conte, Steen Werner Hansen et al.|Journal of Clinical Oncology|2000Cited by 2.3k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Martine Piccart, Michael Untch et al.|The Lancet|2007Cited by 1.5k
Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patientsÁngela Santonja, Emilio Alba, Nuria Ribelles et al.|Cancer Research|2016Cited by 1
Toxicity of prolonged treatment with eribulin (E) in metastatic breast cancer (MBC) patients: Results of the EXTER study.Francisco Ayala, M. Quezada Feijoo, Noelia Martínez-Jáñez et al.|Journal of Clinical Oncology|2015Cited by 0